Turn Downtime Into Cash!
He's showing regular people how they can make a killing as traders right from their homes!
Click here to see how.

Michael M. Rowe Insider Information

COO of Eyenovia
Michael Rowe has been serving as our Vice President, Commercial since October 2019 and, prior to that, since July 2018, as our Vice President, Marketing. From February 2016 to June 2018, Mr. Rowe was head of Global Strategic Marketing, Ophthalmology at Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), where he was responsible for the United States and international commercialization, planning and execution for Rhopressa®, for the lowering of elevated IOP in patients with open-angle glaucoma or ocular hypertension. Previously, he spent 12 years at Allergan plc (NYSE: AGN) in various roles supporting corporate strategic initiatives as well as strategic planning for the company’s worldwide glaucoma franchise, including the development of bimatoprost SR and the global launch of Ganfort® UD. Mr. Rowe also has held senior marketing roles at Bayer Healthcare Pharmaceuticals Inc., Women First HealthCare, Inc. (a former public company) and Pfizer Inc (NYSE: PFE). Mr. Rowe holds an M.Sc. in Human Factors/Experimental Psychology from Rensselaer Polytechnic Institute and a B.A. in Psychology from the State University of New York at Stony Brook.

What is Michael M. Rowe's net worth?

The estimated net worth of Michael M. Rowe is at least $12,600.00 as of May 27th, 2021. Mr. Rowe owns 2,800 shares of Eyenovia stock worth more than $12,600 as of September 18th. This net worth estimate does not reflect any other investments that Mr. Rowe may own. Learn More.

How do I contact Michael M. Rowe?

The corporate mailing address for Mr. Rowe and other Eyenovia executives is 295 MADISON AVENUE SUITE 2400, NEW YORK NY, 10017. Eyenovia can also be reached via phone at (917) 289-1117 and via email at [email protected]

Has Michael M. Rowe been buying or selling shares of Eyenovia?

Michael M. Rowe has not been actively trading shares of Eyenovia during the last quarter. Most recently, on Thursday, May 27th, Michael M. Rowe bought 1,400 shares of Eyenovia stock. The stock was acquired at an average cost of $4.71 per share, with a total value of $6,594.00. Following the completion of the transaction, the chief operating officer now directly owns 2,800 shares of the company's stock, valued at $13,188.

Who are Eyenovia's active insiders?

Eyenovia's insider roster includes Stuart Grant (Major Shareholder), Kenneth Lee, Jr. (Director), Charles Mather, IV (Director), and Michael Rowe (COO).

Are insiders buying or selling shares of Eyenovia?

In the last twelve months, Eyenovia insiders bought shares 12 times. They purchased a total of 328,011 shares worth mmore than $1,277,283.88. The most recent insider tranaction occured on September, 13th when Michael M. Rowe COO bought 1,500 shares worth more than $6,600.00. Insiders at Eyenovia own 20.0 % of the company.

Information on this page was last updated on 9/13/2021.

Michael M. Rowe Insider Trading History at Eyenovia

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/27/2021Buy1,400$4.71$6,594.002,800View SEC Filing Icon  
9/25/2018Buy800$4.23$3,384.00View SEC Filing Icon  
See Full Table

Michael M. Rowe Buying and Selling Activity at Eyenovia

This chart shows Michael M Rowe's buying and selling at Eyenovia by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Eyenovia Company Overview

Eyenovia logo
Eyenovia, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of ophthalmology products. The company offers a piezo-print technology to deliver micro-doses of micro-therapeutics for the eyes. Its products include MicroProst, MicroStat, MicroTears, and MicroPine. The firm is currently focused on the late-stage development of microdosed medications for presbyopia, myopia progression, and mydriasis. The company was founded by Sean Ianchulev on March 12, 2014 and is headquartered in New York, NY.
Read More

Today's Range

Now: $4.50
Low: $4.41
High: $4.64

50 Day Range

MA: $4.61
Low: $3.97
High: $5.64

2 Week Range

Now: $4.50
Low: $2.90
High: $7.72


155,497 shs

Average Volume

159,400 shs

Market Capitalization

$116.77 million

P/E Ratio


Dividend Yield



Turn Downtime Into Cash!
He's showing regular people how they can make a killing as traders right from their homes!
Click here to see how.